Effect of naringin and cisplatin combination on cell viability and cell death in bladder cancer cells

N.A.

Makale detayları

Effect of naringin and cisplatin combination on cell viability and cell death in bladder cancer cells

Yazarlar:

N.A.

Yayıncı:

Marmara University

Ana Başlıklar:

Pharmacology and Pharmaceutical Sciences (Other)

Dergi:

Journal of Research in Pharmacy Vol.29 Issue 2, pp.673-681

Belge Tipi:

Makale

Yayın Tarihi:

8/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001341713

pISSN:

2630-6344

Anahtar kelimeler:

Özet:

 Bladder cancer is a prevalent malignancy characterized by high recurrence rates and limited therapeutic options, particularly due to resistance and toxicity associated with cisplatin therapy. Bladder cancer remains a significant global health concern, and while cisplatin is a cornerstone of treatment, its efficacy is often limited by resistance and toxicity. Therefore, there is a critical need for novel agents that can enhance cisplatins effects while mitigating its drawbacks. This study investigates the potential of naringin, a natural flavonoid, to exhibit antiproliferative and proapoptotic effects in human bladder cancer cell lines HTB-9 and HT-1376, both as a monotherapy and in combination with cisplatin. Cytotoxicity was assessed via the MTT 3-4,5-dimetiltiazol-2-il-2,5 difeniltetrazoliumbromid assay, and apoptosis was evaluated using Annexin VPI staining and caspase 37 activation assays. Results demonstrated that naringin reduced cell viability in a dose-dependent manner in both cell lines. When combined with cisplatin, naringin significantly enhanced the antiproliferative and pro-apoptotic effects compared to either treatment alone. Caspase 37 activity was markedly elevated in the combination groups, indicating an amplified apoptotic response. These findings suggest that naringin can potentiate cisplatins efficacy and could serve as a promising adjunctive therapy in bladder cancer treatment. Further studies are warranted to explore the underlying mechanisms and potential clinical applications of naringin in enhancing cisplatin-based chemotherapy.

 Bladder cancer is a prevalent malignancy characterized by high recurrence rates and limited therapeutic options, particularly due to resistance and toxicity associated with cisplatin therapy. Bladder cancer remains a significant global health concern, and while cisplatin is a cornerstone of treatment, its efficacy is often limited by resistance and toxicity. Therefore, there is a critical need for novel agents that can enhance cisplatins effects while mitigating its drawbacks. This study investigates the potential of naringin, a natural flavonoid, to exhibit antiproliferative and proapoptotic effects in human bladder cancer cell lines HTB-9 and HT-1376, both as a monotherapy and in combination with cisplatin. Cytotoxicity was assessed via the MTT 3-4,5-dimetiltiazol-2-il-2,5 difeniltetrazoliumbromid assay, and apoptosis was evaluated using Annexin VPI staining and caspase 37 activation assays. Results demonstrated that naringin reduced cell viability in a dose-dependent manner in both cell lines. When combined with cisplatin, naringin significantly enhanced the antiproliferative and pro-apoptotic effects compared to either treatment alone. Caspase 37 activity was markedly elevated in the combination groups, indicating an amplified apoptotic response. These findings suggest that naringin can potentiate cisplatins efficacy and could serve as a promising adjunctive therapy in bladder cancer treatment. Further studies are warranted to explore the underlying mechanisms and potential clinical applications of naringin in enhancing cisplatin-based chemotherapy.

 Bladder cancer is a prevalent malignancy characterized by high recurrence rates and limited therapeutic options, particularly due to resistance and toxicity associated with cisplatin therapy. Bladder cancer remains a significant global health concern, and while cisplatin is a cornerstone of treatment, its efficacy is often limited by resistance and toxicity. Therefore, there is a critical need for novel agents that can enhance cisplatins effects while mitigating its drawbacks. This study investigates the potential of naringin, a natural flavonoid, to exhibit antiproliferative and proapoptotic effects in human bladder cancer cell lines HTB-9 and HT-1376, both as a monotherapy and in combination with cisplatin. Cytotoxicity was assessed via the MTT 3-4,5-dimetiltiazol-2-il-2,5 difeniltetrazoliumbromid assay, and apoptosis was evaluated using Annexin VPI staining and caspase 37 activation assays. Results demonstrated that naringin reduced cell viability in a dose-dependent manner in both cell lines. When combined with cisplatin, naringin significantly enhanced the antiproliferative and pro-apoptotic effects compared to either treatment alone. Caspase 37 activity was markedly elevated in the combination groups, indicating an amplified apoptotic response. These findings suggest that naringin can potentiate cisplatins efficacy and could serve as a promising adjunctive therapy in bladder cancer treatment. Further studies are warranted to explore the underlying mechanisms and potential clinical applications of naringin in enhancing cisplatin-based chemotherapy.

 Bladder cancer is a prevalent malignancy characterized by high recurrence rates and limited therapeutic options, particularly due to resistance and toxicity associated with cisplatin therapy. Bladder cancer remains a significant global health concern, and while cisplatin is a cornerstone of treatment, its efficacy is often limited by resistance and toxicity. Therefore, there is a critical need for novel agents that can enhance cisplatins effects while mitigating its drawbacks. This study investigates the potential of naringin, a natural flavonoid, to exhibit antiproliferative and proapoptotic effects in human bladder cancer cell lines HTB-9 and HT-1376, both as a monotherapy and in combination with cisplatin. Cytotoxicity was assessed via the MTT 3-4,5-dimetiltiazol-2-il-2,5 difeniltetrazoliumbromid assay, and apoptosis was evaluated using Annexin VPI staining and caspase 37 activation assays. Results demonstrated that naringin reduced cell viability in a dose-dependent manner in both cell lines. When combined with cisplatin, naringin significantly enhanced the antiproliferative and pro-apoptotic effects compared to either treatment alone. Caspase 37 activity was markedly elevated in the combination groups, indicating an amplified apoptotic response. These findings suggest that naringin can potentiate cisplatins efficacy and could serve as a promising adjunctive therapy in bladder cancer treatment. Further studies are warranted to explore the underlying mechanisms and potential clinical applications of naringin in enhancing cisplatin-based chemotherapy.

Makale detayları

Effect of naringin and cisplatin combination on cell viability and cell death in bladder cancer cells

Yazarlar:

N.A.

Yayıncı:

Marmara University

Ana Başlıklar:

Pharmacology and Pharmaceutical Sciences (Other)

Dergi:

Journal of Research in Pharmacy Vol.29 Issue 2, pp.673-681

Belge Tipi:

Makale

Yayın Tarihi:

8/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001341713

pISSN:

2630-6344

Apoptosis

bladder cancer

caspase 3/7

cisplatin

naringin

HTB-9

HT-1376

Sayı

Makale detayları

Yazarlar: N.A.

Yayıncı: Marmara University

Ana Başlıklar: Pharmacology and Pharmaceutical Sciences (Other)

Dergi: Journal of Research in Pharmacy Vol.29 Issue 2, pp.673-681

Belge Tipi: Makale

Yayın Tarihi: 8/2025

Belge Dili: İngilizce

Document ID (Org No.): 2001341713

pISSN: 2630-6344

Sayı

Yazarlar:

N.A.

Yayıncı:

Marmara University

Ana Başlıklar:

Pharmacology and Pharmaceutical Sciences (Other)

Dergi:

Journal of Research in Pharmacy Vol.29 Issue 2, pp.673-681

Belge Tipi:

Makale

Yayın Tarihi:

8/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001341713

pISSN:

2630-6344